(Berlin, 19-22 February)
New findings highlight the commitment of Alfasigma to improving the lives of people living with Ulcerative Colitis
Alfasigma is excited to announce that new findings from the multicenter-multicountry GALOCEAN (ph4) and SELECTION (ph3) studies, focusing on patients with moderate to severe Ulcerative Colitis, will be presented at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) 2025.[1] The congress will take place from February 19–22 in Berlin, Germany, where Alfasigma will be located at booth #32 in Hall 4.2.
Thijs Hendrikx, Head of Global Medical Affairs, said: “At Alfasigma, we are deeply committed to advancing the care of people living with Gastrointestinal diseases such as Ulcerative Colitis, from those with milder symptoms to those facing more severe stages of their condition. By partnering with patients and healthcare professionals, we aim to drive the development of innovative solutions to improve the quality of life of all patients living with gastrointestinal conditions”.
Link to the abstracts of the GALOCEAN and SELECTION studies accepted for presentation at ECCO 2025:
- https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i2094/7971928
- https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i2087/7971753
- https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i1884/7967892
Alfasigma will also host a Satellite Symposium “Moderately Active UC in the Spotlight”, which takes place on Thursday, February 20, 2025, 19:00-20:00 in room A4 of the congress center.
Alfasigma Commitment in Gastroenterology
This participation at ECCO Congress underlines Alfasigma’s commitment to Gastroenterology and in IBD. In collaboration with the medical community and patient associations, Alfasigma strives to provide tangible and viable solutions to gastro-intestinal disorders, ranging from prevalent diseases where gut microbiota plays an essential role, such as IBD (Inflammatory Bowel Disease), to functional disorders (e.g. IBS) like bacterial gastroenteritis, and gastro-esophageal reflux and liver rare diseases.
About Ulcerative Colitis (UC)
Ulcerative colitis is an inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the digestive tract. Ulcerative colitis affects the innermost lining of the large intestine, also called the colon, and rectum and it is an increasingly prevalent inflammatory disease that causes disruptive symptoms and reduced HRQoL (Health-Related Quality of Life).
[1] Abstracts accepted for presentation at ECCO 2025 are published in the Journal of Crohn’s and Colitis.